Startseite>>Signaling Pathways>> Metabolism>> Reproductive Biology>>Estrone-3-Glucuronide (sodium salt hydrate)

Estrone-3-Glucuronide (sodium salt hydrate) (Synonyms: E1G, Estrone Glucuronide, Estrone β-D-Glucuronide)

Katalog-Nr.GC49254

A metabolite of 17β-estradiol

Products are for research use only. Not for human use. We do not sell to patients.

Estrone-3-Glucuronide (sodium salt hydrate) Chemische Struktur

Cas No.: N/A

Größe Preis Lagerbestand Menge
1 mg
43,00 $
Auf Lager
5 mg
150,00 $
Auf Lager
10 mg
280,00 $
Auf Lager
25 mg
643,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Estrone-3-Glucuronide is a metabolite of the primary premenopausal estrogen 17β-estradiol .1,2 Urinary levels of estrone-3-Glucuronide peak approximately 36 hours prior to ovulation and have been used as a marker of fertility in women.

1.Blackwell, L.F., Brown, J.B., and Cooke, D.Definition of the potentially fertile period from urinary steroid excretion rates. Part II. A threshold value for pregnanediol glucuronide as a marker for the end of the potentially fertile period in the human menstrual cycleSteroids63(1)5-13(1998) 2.Adlercreutz, H., Brown, J., Collins, W., et al.The measurement of urinary steroid glucuronides as indices of the fertile period in womenJ. Steroid Biochem.17(6)695-702(1982)

Bewertungen

Review for Estrone-3-Glucuronide (sodium salt hydrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Estrone-3-Glucuronide (sodium salt hydrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.